Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The special resolution for the acquisition was approved by a high percentage of shareholder votes
The acquisition is subject to the approval of the Superior Court of Québec and other closing conditions, with expected completion by January 28, 2026.
The acquisition signals a strategic shift in Repare's future direction, leveraging the combined expertise in precision oncology and xenotransplantation for potential synergies and innovation in the oncology research landscape.
Approval of Acquisition
99.76% of the votes cast by shareholders approved the acquisition by XenoTherapeutics, Inc., showcasing strong investor confidence in the strategic alignment and potential benefits of the acquisition.
Compensation Approval
Shareholders approved the compensation to be paid to the named executive officers based on the acquisition, ensuring alignment of interests and incentivizing leadership for successful integration and post-acquisition performance.
Liquidation Vote
Shareholders voted in favor of voluntary liquidation and dissolution of the Company if the arrangement is terminated, indicating readiness to act swiftly and efficiently in any scenario to maximize shareholder value.
- Repare Therapeutics Inc., a clinical-stage precision oncology company, is positioned to enhance its research and development capabilities through the acquisition by XenoTherapeutics, Inc., a Massachusetts-based research foundation specializing in xenotransplantation.
- The integration of expertise from Repare and XenoTherapeutics is expected to result in cross-pollination of ideas, accelerated innovation, and potential breakthroughs in precision medicine, advancing the fight against cancer and other complex diseases.
- The approval of the acquisition signifies a strategic milestone for Repare, setting the stage for collaborative research initiatives, expanded clinical trials, and the development of novel therapies that could reshape the landscape of precision oncology.
The approval by Repare shareholders marks a significant step towards the acquisition by XenoTherapeutics, Inc., paving the way for transformative advancements in precision oncology and xenotransplantation research. The strategic synergy between the two entities is poised to drive innovation, foster scientific discoveries, and deliver tangible value to patients, investors, and the broader healthcare ecosystem.